使用PrEP的MSM与HIV感染者MSM的肛门HPV负荷及细胞学异常相当
比利时队列研究比较使用PrEP的MSM与HIV感染者MSM的肛门高危HPV感染和肛门细胞学异常,发现两组患病率相当,均超过半数参与者存在细胞学异常。性 debut 后接种HPV疫苗与较低的高危HPV患病率相关,但该发现为探索性且样本量有限。
要点
- 使用PrEP的MSM肛门高危HPV感染和细胞学异常负担与HIV感染者MSM相当。
- 两组均超过半数参与者存在肛门细胞学异常。
- 性 debut 后接种HPV疫苗与较低高危HPV患病率相关,但证据有限。
核心结论
- 使用PrEP的MSM与HIV感染者MSM的肛门高危HPV感染和异常细胞学负担相当。
研究设计与样本
- 比利时队列研究,比较使用PrEP的MSM与HIV感染者MSM的肛门高危HPV感染和肛门细胞学异常。
主要发现
- 使用PrEP的MSM高危肛门HPV感染患病率与HIV感染者MSM相当。
- 两组中超过半数参与者存在肛门细胞学异常。
- 性 debut 后接种HPV疫苗与较低的高危HPV患病率相关,但为探索性且基于有限数量。
临床怎么用
- 筛查指南目前聚焦HIV感染者和未感染HIV的老年MSM,本研究提示使用PrEP的MSM可能也需纳入筛查和预防考量。
局限性
- 性 debut 后接种HPV疫苗与较低高危HPV患病率相关的发现为探索性且基于有限数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Anal cancer and its precursors are strongly associated with persistent high-risk human papillomavirus (HPV) infection, with the highest burden described in men who have sex with men (MSM) living with HIV; screening guidelines therefore focus on people living with HIV and older MSM without HIV, while emerging evidence suggests that MSM using pre-exposure prophylaxis (PrEP) may carry a similar burden. WHAT THIS STUDY ADDS In this Belgian cohort, MSM using PrEP showed a prevalence of high-risk anal HPV infection and abnormal anal cytology comparable to that observed in MSM living with HIV, with more than half of participants in both groups presenting cytological abnormalities. Post-sexual-debut HPV vaccination was associated with a lower prevalence of HR-HPV, although this finding was exploratory and based on limited numbers. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These...
引用
- Sexually Transmitted Infections (BMJ):Comparable anal HPV burden and abnormal cytology in MSM using PrEP and MSM living with HIV: implications for screening and prevention
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。